In conclusion, for the first time, our results demonstrated that inhibition of AKT triggers not only apoptosis but also a p53/SIRT6/PARP1 dependent parthanatos, which may uncover novel therapeutic strategies for CRC treatment. This evidence concerns the gene TP53 and colorectal carcinoma.